What is the difference between ARA-290 and SS-31?

ARA-290: Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing SS-31: Targets cardiolipin in inner mitochondrial membrane; stabilizes cristae structure; enhances electron transport chain efficiency; reduces mitochondrial ROS

Is ARA-290 FDA approved?

ARA-290 is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

Is SS-31 FDA approved?

SS-31 is FDA approved (FDA status current as of 2025-09-19). This regulatory status is provided for research and educational context only.

How is ARA-290 administered in research settings?

In research settings, ARA-290 is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is SS-31 administered in research settings?

In research settings, SS-31 is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›ARA-290 vs SS-31

Peptide Comparison

ARA-290 vs SS-31

Name: ARA-290 vs SS-31 — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Longevity & Cellular peptides.

ARA-290

Cibinetide

LongevityInvestigationalResearch Only

Half-life: ~2 min (IV); ~10–20 min (SC)

17 providers listed

Full ARA-290 profile →

SS-31

Elamipretide

LongevityFDA ApprovedPrescription

Half-life: ~2-3 hours

51 providers listed

Full SS-31 profile →

Bottom line

SS-31 is FDA-approved, while ARA-290 is investigational — the clearest structural difference between them.

Quick Verdict

ARA-290

Half-life

~2 min (IV); ~10–20 min (SC)

SS-31

Half-life

~2-3 hours

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	SS-31
Further along in FDA review	SS-31
Less frequent dosing (longer half-life)	SS-31
More provider options (17 vs 51)	SS-31

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

ARA-290

SS-31

Mechanism Family

Longevity & Cellular

Half-life

~2 min (IV); ~10–20 min (SC)

~2-3 hours

FDA Status

investigational

approved

Admin Routes

subcutaneous, intravenous

Availability

Research Only

Prescription

Providers

17 listed

51 listed

FDA Update

—

Sep 2025

Avail. Notes

Non-hematopoietic EPO analog (cibinetide) by Araim Pharma. Phase 3 for sarcoidosis peripheral neuropathy; Dutch conditional marketing authorisation applied for. No FDA approval. Investigational.

Mitochondria-targeting tetrapeptide (elamipretide) by Stealth BioTherapeutics. FDA issued CRL for Barth syndrome NDA 2021 (additional data required). Continued by Mitobridge/AstraZeneca. Investigational.

Research Evidence

ARA-290

RCT · 2 key studies · most recent 2026

SS-31

RCT · 10 key studies · most recent 2026

Research Citations

ARA-290

RCT2017 · Investigative Ophthalmology & Visual Science

Cibinetide (ARA 290) reduces small nerve fiber pathology in sarcoidosis patients

Animal2026 · Neurobiol Dis

Immunometabolic dysregulation drives selective executive cognitive dysfunction in male db/db mice.

SS-31

RCT2017 · Circulation: Cardiovascular Interventions

Intrarenal Infusion of Elamipretide (MTP-131) During Stenting in Patients With Atherosclerotic Renovascular D…

RCT2017 · Circulation: Heart Failure

Elamipretide (MTP-131) Alters the Landscape of Myocardial Lipids and Reduces Oxidative Stress Following Cardi…

Animal2026 · Redox Biol

Peroxiredoxin Ⅲ safeguards cardiac function against doxorubicin by regulating mitochondrial quality control v…

Animal2026 · ACS Nano

Protective Effect of Mitochondria-Targeted Polydopamine Nanoparticles in Alleviating Hepatic Ischemia-Reperfu…

+6 more

About ARA-290

Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing

Research Areas

neuropathic pain relieftissue repairanti-inflammatorymetabolic improvement

About SS-31

Targets cardiolipin in inner mitochondrial membrane; stabilizes cristae structure; enhances electron transport chain efficiency; reduces mitochondrial ROS

Research Areas

mitochondrial protectioncardioprotectionenergy productionanti-aging

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

ARA-290

Reported (Unverified — Pending Clinical Review)

active erythrocytosis

No established clinical contraindications

SS-31

No structured contraindication profile is available for this compound yet. This compound is FDA-approved — consult the official prescribing information or a qualified clinician.

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

Price (per mg)

ARA-290

$4.95/mg

$3.91 – $5.56 range

34 vendors

View price index →Find providers →

SS-31

$5.00/mg

$3.64 – $6.00 range

31 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

ARA-290

17 listed

Browse directory →

Providers offering

SS-31

51 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Longevity & Cellular Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). ARA-290 vs SS-31 — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/ara-290/ss-31

https://peptidebase.io/peptides/compare/ara-290/ss-31 Methodology License Download JSON Download CSV